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A Literature Review of Dietary Resveratrol Supplements:  
Do they Mimic the Effects of Endurance Exercise? 
 
Abstract 
 Resveratrol is a polyphenol whose best dietary sources are red wine, red grapes, and 
peanuts. It has become a popular dietary supplement because it has been suggested to be 
responsible for the cardioprotective effects of red wine. Resveratrol may also mimic the effects 
of calorie-restriction to increase longevity, as shown in several animal studies. Resveratrol is 
thought to exert its effects primarily by activating a class of proteins called sirtuins. These 
proteins are NAD+-dependent deacetylases that potentially regulate metabolism and gene expression. 
A further increase in the popularity of resveratrol supplements occurred following reports that it 
may also function as an exercise mimetic, inducing some of the same physiological adaptations 
in skeletal muscle that are observed with endurance exercise training. Through the AMPK-
SIRT1-PGC-1α pathway, resveratrol has been shown to induce transcription of nuclear encoded 
mitochondrial proteins, and thereby induce mitochondrial biogenesis. In animal studies, the 
amount of resveratrol needed to induce these effects is considerably high. Commercially 
available supplements may not contain enough resveratrol to be effective as exercise mimetics. 
However, some supplements may improve glucose tolerance and insulin sensitivity, as shown in 
human studies. 
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Introduction 
 Phenolic compounds contain one or more aromatic rings with a hydroxyl group attached 
to at least one of these rings (2). Phenolics are generally divided into two categories, flavonoids 
and non-flavonoids. Flavonoids are polyphenolic compounds comprising of 15 carbons, with 2 
aromatic rings connected by a 3-carbon bridge (2). There are several categories of non-flavonoid 
phenolic compounds; resveratrol is a member of a group of non-flavonoid polyphenolics known 
as stilbenes that have a general structure of two 6-carbon phenolic rings joined by a two carbon 
bridge (29). These compounds tend to be produced by plants in defense against pathogens. High 
intake of dietary phenols has been associated with a reduction in degenerative diseases, such as 
cardiovascular disease, cancer, obesity, and diabetes (29). 
 Resveratrol (3,5,4'-trihydroxystilbene) is a polyphenol commonly found in foods such as 
red wine, grapes, and peanuts and has been shown to have several health benefits (6, 52). 
Resveratrol was first discovered in the 1940's and has hence forth been used to explain the 
“French paradox” (52). The “French paradox” is a term used to refer to the phenomenon in 
which although the French consume a diet high in saturated fat they have a two- to three- fold 
lower incidence of cardiovascular related diseases when compared to other countries, such as the 
U.S. (11). This theory suggests that resveratrol has cardioprotective effects which may be 
attributed to resveratrol's ability to improve vascular function by inhibiting platelet aggregation, 
reducing blood pressure, and increasing the expression of the enzyme responsible for the 
synthesis of the vasodilator nitric oxide (NO) (12, 43, 47, 57).  Bradamante et al. discovered that 
resveratrol supplementation creates a “preconditioning” affect which reduces the damage caused 
by acute ischemia and reperfusion injuries, which could be a result of improvements in 
  3 
cardiovascular function (5). These improvements in cardiovascular function may also explain 
why resveratrol has also been shown to delay/prevent neurodegenerative disease and stroke-
induced brain damage (4, 44).  
 Resveratrol has been shown to increase longevity. Resveratrol supplementation has been 
shown to increase lifespan of fish, flies, and worms, and has natural antioxidant properties (3). It 
is thought that resveratrol affects longevity through sirtuin activation. Sirtuins act on gene 
transcription, DNA repair, cell signaling, and apoptosis allowing them to play a key role in 
longevity (11). Through sirtuin activity, resveratrol supplementation has also been shown to 
improve longevity in mice by protecting against cancer (6). 
 Resveratrol may mimetic the effects of endurance exercise and serve as a remedy for age-
related chronic diseases. Like endurance training, resveratrol has been suggested to improve 
endurance capacity by enhancing lipid metabolism through an increase in mitochondrial content 
and a reduction in reactive oxygen species (ROS) produced by mitochondria (40, 55). The 
outcome of resveratrol supplementation improves cellular metabolic processes in humans and 
may possibly prevent or delay many chronic diseases (53). 
Understanding the mechanism of action of resveratrol is critical for development of drugs 
to combat chronic diseases such as cardiovascular disease, diabetes, cancer, and obesity. 
Development of more potent and molecularly specific resveratrol-derived agents could produce a 
drug to treat metabolic disorders (45, 54). 
Mechanism of physiological adaptations in response to endurance exercise 
 Endurance exercise activates an array of metabolic pathways. “Skeletal muscle is a 
malleable tissue capable of altering its type and amount of protein in response to disruptions to 
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cellular homeostasis” (14). Endurance exercise is known to enhance cardiovascular function and 
aerobic capacity through increases in mitochondrial content within muscle as well as increasing 
the capillary-to-muscle fiber ratio (24). Increased contractile activity is the initial signal in 
pathways responsible for exercise induced adaptations (24). Contractile activity causes ATP 
breakdown and calcium influx, both of which signal activation of downstream kinases (24).  
Increases in the AMP:ATP ratio within the cell, as seen during exercise, stimulates the 
energy sensing enzyme AMP-protein activated kinase (AMPK) (24). Activation of AMPK 
induces activation of peroxisome proliferator-activated receptor gamma coactivator 1-alpha 
(PGC-1α) (27).  
PGC-1α is a coactivator for several nuclear transcription factors, such as peroxisome 
proliferator-activated receptor gamma (PPAR-γ) and nuclear respiratory factor 1 and 2 (NRF1 & 
2) (42). These nuclear transcription factors are assembled on the DNA promoter region and 
stimulate the expression of nuclear encoded mitochondrial proteins (NEMP), which are required 
for mitochondrial gene expression, replication, and assembly.  
AMPK activation also triggers silent mating type information regulation 2 homolog 1 
(SIRT1) activation by AMPK-derived increases in its substrate, NAD+ (9, 10). SIRT1 is a NAD+-
dependent deacetylase enzyme  and is therefore considered an energy sensing enzyme (58). 
SIRT1 is known to deacetylate histones as well as non-histone proteins rich in lysine in an NAD+ 
consuming reaction (13). SIRT1 deacetylates PGC-1α and positively regulates its activity (19, 
48). SIRT1 also has the potential to deacetylate kinases responsible for the phosphorylation of 
AMPK (28). Therefore, SIRT1 and AMPK are considered to reciprocally activate each other 
(25). 
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PGC-1α is a key regulator of adaptations to endurance training (36). PGC-1α coactivates 
nuclear transcription factors responsible for gene transcription of NEMP involved in 
mitochondrial biogenesis (49). Post-translational modification of PGC-1α affects its activation 
status (24). Deacetylation of PGC-1α by SIRT1 improves its ability to promote expression of 
NEMP (48). PGC-1α can also be activated via phosphorylation by AMPK (30).  
PGC-1α transcription and activation have been shown to increase during metabolic stress, 
exercise and calorie restriction (19). PGC-1α regulates mitochondrial biogenesis through post-
translational modification of existing PGC-1α protein and increases in PGC-1α protein 
expression (8, 60).  
Overexpression of PGC-1α correlates with increases in mitochondrial content and a shift 
towards a more oxidative fiber type composition (23, 46). Increases in mitochondrial content 
were not seen in PGC-1α-knockout mice in response to energy deprivation (62). The studies 
previously discussed support the conclusion that PGC-1α is the final regulator of mitochondrial 
biogenesis. Therefore, anything that artificially increases PGC-1α activity may lead to an 
increase in mitochondrial biogenesis. 
Mechanism of resveratrol supplementation 
 The mechanism through which resveratrol induces metabolic adaptations involves a 
number of cellular responses. By activating SIRT1 and/or AMPK, increased PGC-1α activation 
follows and transcription of NEMP occurs. Figure 1 shows how endurance exercise and exercise 
mimetics, such as resveratrol, might target the same cellular pathways; therefore inducing the 
same physiological adaptations. 
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SIRT1 and mitochondrial biogenesis 
 Mitochondrial biogenesis is SIRT1-mediated. Price et al. examined the effects of SIRT1 
overexpression on mitochondrial biogenesis. Price used transgenically altered mice to induce 
SIRT1 overexpression. Figure 2A shows the results of SIRT1 overexpression on PGC-1α mRNA 
content. A significant increase in PGC-1α mRNA content was shown in SIRT1 overexpression 
mice compared to wild type mice (p<0.05). SIRT1-mediated activation of existing PGC-1α 
protein increases PGC-1α expression, due to self-induced promoter activation (24, 60). Therefore 
increases in PGC-1α mRNA in response to SIRT1 overexpression suggests increased PGC-1α 
activation. Increases in PGC-1α activity are associated with increased mitochondrial biogenesis  
Figure 1. Proposed mechanism of action of exercise mimetics. 
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(22). Mitochondrial DNA content was also significantly increased in SIRT1 overexpression 
mice, figure 2B (p<0.05). SIRT1 plays a key role in acute and chronic exercise-mediated 
mitochondrial biogenesis (16, 21). The data in figure 2 provides evidence that SIRT1 
overexpression is sufficient to induce mitochondrial biogenesis, allowing SIRT1 to function as an 
exercise mimetic.  
SIRT1 mRNA levels are elevated following endurance exercise. In humans, SIRT1 
mRNA has been shown to increase after marathon running and after a three hour cycling session 
(18, 38). SIRT1 protein content increases in humans after a single bout of cycling and in rats 
following 45 minutes treadmill running (20, 51). Therefore, anything that increases SIRT1 
activity and content may also increase PGC-1α activity, resulting in mitochondrial biogenesis.  
Resveratrol induces mitochondrial biogenesis through SIRT1. To determine the role of 
SIRT1 in resveratrol-mediated mitochondrial biogenesis SIRT1-knockout mice were used.  
Figure 2. (A) PGC-1α mRNA content in gastrocnemius muscle of resveratrol-treated 
wild type and SIRT1 overexpression mice. (B) Mitochondrial DNA content in 
gastrocnemius muscle of resveratrol-treated wild type and SIRT1 overexpression 
mice. Values are expressed as mean ± SEM (*p<0.05). 
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Figure 3 shows the effects of SIRT1-knockout on mitochondrial DNA content in mice treated 
with resveratrol. Wild type resveratrol-treated mice display a significant increase in 
mitochondrial DNA content (p<0.05). On the contrary, SIRT1-knockout mice did not display a 
significant change in mitochondria content when treated with resveratrol. These results imply 
that SIRT1 plays a key role in resveratrol-mediated mitochondrial biogenesis, since adaptations 
were not seen in SIRT1-knockout mice.  
This study is consistent with the finding that SIRT1 and PGC-1α are activated by 
resveratrol, altering muscle gene expression and inducing mitochondrial biogenesis (61). In other 
studies, SIRT1-knockout mice show a decrease in PGC-1α mRNA content and increased PGC-
1α acetylation levels (1, 19). Treatment with SIRT1 inhibitors, such as nicotinamide, decreases 
the expression of mitochondrial genes regulated by PGC-1α (19). Resveratrol induces SIRT1-
Figure 3. Mitochondrial DNA content in gastrocnemius muscle of resveratrol-treated 
wild type and SIRT1-knockout mice. Values are expressed as mean ± SEM (*p<0.05). 
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mediated mitochondrial biogenesis by increased deacetylation  of PGC-1α (13). This leads to the 
conclusion that resveratrol-mediated physiological adaptations may be SIRT1-dependent.  
AMPK and SIRT1 activation 
 Since AMPK is an activator of SIRT1, then perhaps resveratrol-mediated SIRT1 
activation is not a direct effect, but rather an indirect outcome of resveratrol-mediated AMPK 
activation (9). To test this hypothesis and determine if AMPK is required for resveratrol-induced 
mitochondrial biogenesis, Um et al. used genetically modified AMPK-knockout mice.  
In wild type mice, resveratrol treatment significantly increased PGC-1α mRNA content 
(p<0.05), shown in figure 4A. AMPK increases SIRT1 activity in response to increases in NAD+ 
levels, which leads to the activation of PGC-1α, resulting in increased PGC-1α mRNA (9, 27). 
There was no significant change in PGC-1α mRNA content in AMPK-knockout mice. This 
corresponds to significant decreases in PGC-1α deacetylation in AMPK-knockout mice (10). 
AMPK activation induces SIRT1-mediated activation of PGC-1α as a result of elevated NAD+ 
levels, the substrate for SIRT1 (9). SIRT1-mediated deacetylation of PGC-1α requires functional 
AMPK (10).  
Figure 4B shows significant increase in mitochondrial DNA content in resveratrol-treated 
wild type mice (p<0.05). However, AMPK-knockout mice did not show a significant change in 
mitochondrial DNA content when treated with resveratrol. These data suggest that resveratrol 
cannot activate SIRT1 without AMPK (52). The ability of resveratrol to function as an exercise 
mimetic may be AMPK-dependent. 
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Physiological Adaptations Seen With Resveratrol Supplementation 
 Lagouge et al. demonstrated that resveratrol supplementation in mice induces 
mitochondrial biogenesis and improves aerobic capacity (figure 5). Metabolic adaptations can be 
attributed to regulation of gene transcription (17). Figure 5 provides evidence that resveratrol 
induces mitochondrial biogenesis, confirmed by the increase in VO2max and exercise endurance 
(p<0.05). Resveratrol-mediated activation of AMPK elevates intracellular NAD+ levels (45, 54). 
Through SIRT1 deacetylation, resveratrol reduces the level of PGC-1α acetylation in wild type 
mice (10). Induced mitochondrial biogenesis and function is attributed to PGC-1α activation and 
mediates muscle fiber-type switching (37). Resveratrol supplementation in mice was shown to 
increase aerobic capacity as demonstrated in figure 5A & B, due to significant increases in both 
VO2max and distance run at exhaustion.  
Resveratrol has been shown to stimulate a shift towards a more oxidative phenotype. This 
is achieved by a reduction in the amount of type IIb highly glycolytic fast-twitch fibers and a rise  
Figure 4. (A) PGC-1α mRNA content in resveratrol-treated and nontreated wild type 
and AMPK-knockout mice. (B) Mitochondrial DNA content in resveratrol-treated and 
nontreated wild type and AMPK-knockout mice. Values are expressed as mean ± SEM 
(**p<0.01 and *p<0.05). 
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in the amount of type IIa and IIx oxidative fast-twitch fibers (45). The conversion of glycolytic 
fast-twitch fibers to oxidative fast-twitch fibers, which are mitochondria rich, improves physical 
endurance (33). Resveratrol-treated mice demonstrated a 2-fold increase in distance ran at 
exhaustion (figure 5B), suggesting an increase in exercise endurance.  
Other adaptations induced by resveratrol supplementation include increased metabolic 
rate, decreased fat mass, decreased body weight, increased glucose tolerance, and increased 
insulin sensitivity (41, 54). 
 In humans, resveratrol supplementation leads to several cellular adaptations. To 
determine if resveratrol-mediated adaptations seen in animal studies are also seen in humans, a 
double-blind cross-over study was performed (53). Eleven obese but otherwise healthy men were 
given either placebo or resveratrol, 150mg/day, for thirty days. Figure 6 shows the effects of 
resveratrol on citrate synthase activity, which is used as a measure of mitochondrial content. 
Decreased citrate synthase activity is associated with mitochondrial dysfunction, as seen in 
diabetes (32). Prolonged activation of AMPK increases citrate synthase activity (59). However,  
Figure 5. (A) Maximum VO2 consumption in gastrocnemius muscle of resveratrol-
treated and nontreated mice (*p<0.05). (B) Average distance run at exhaustion in 
resveratrol-treated and nontreated mice (*p<0.05). Values represent means ± SEM. 
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total mitochondrial content did not increase (53). Resveratrol supplementation in humans appears 
to improve insulin sensitivity, reduce plasma triglyceride levels, increase total fat oxidation, and 
reduce systolic blood pressure (53).  
Timmers et al. suggest that the adaptations induced by resveratrol are as result of 
increased mitochondrial efficiency. This is due to increased citrate synthase activity rather than 
an increase in mitochondrial abundance, since mitochondrial DNA copy number did not increase. 
These data suggest that thirty days may not be long enough to see the full effects of resveratrol 
supplementation. Also, the mechanism of resveratrol-mediated mitochondrial biogenesis may be 
more complex in human models than the animal models previously studied. 
Dosage 
 The adaptations seen with resveratrol supplementation greatly depend on the dosage used. 
Resveratrol is rapidly absorbed by enterocytes within the small intestines (52). An oral dose of 
25 mg resveratrol results in plasma concentrations in the order of nanomolars (15, 31, 56). 
Figure 6. Citrate synthase activity in vastus lateralis muscle of resveratrol treated and 
nontreated humans (*p<0.05).  Values represent means ± SEM. 
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Resveratrol is rapidly metabolized by the liver and plasma concentrations peak within 
approximately 30 minutes (52). Red wine has a resveratrol concentration of approximately 84 ng 
per 100 g of wine (50). The concentration of resveratrol required to activate SIRT1 is in the 
micromolar range and is probably not achievable by diet alone (6). Resveratrol concentrations in 
vivo may not be high enough to effectively induce a metabolic response (6).  
 Adaptations seen in animal studies were dependent on the dose of resveratrol used. In 
obese rodent models, a “high” dose of resveratrol, 400 mg/kg/day, was able to improve insulin 
sensitivity and reduce body weight (34). Treatment with a “moderate” dose, 25-30 mg/kg/day, 
induced a SIRT1-dependent shift towards a more oxidative phenotype (45). Muscle fiber type 
switching is attributed to increased mitochondrial biogenesis and improved mitochondrial 
function (24). These results suggest that a moderate dose of resveratrol is more effective at 
stimulating mitochondrial biogenesis. 
 The resveratrol dosage required for physiological adaptations in humans may be different 
than that required for animals. Timmers et al. used a dose of 150 mg/day. Although, this dosage 
is approximately 200-fold lower than the dosage used by Lagouge et. al, (200-400 mg/kg/day), 
plasma resveratrol concentrations in humans showed a 2-fold or greater increase compared to 
plasma concentrations seen in animal studies when using the higher dosage (34). This could be 
due to differences in the rate of metabolism of resveratrol between humans and mice. With a 
dosage of 150 mg/day of resveratrol, improvements in glucose tolerance and insulin sensitivity 
were seen, however, increases in mitochondrial biogenesis were not. 
 The precise dosage required to see resveratrol-induced mitochondrial biogenesis in 
humans has yet to be determined. However, if the effective dosages of resveratrol used in animal 
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studies were extrapolated to a reference 70kg person, the dosage required to see results would be 
1.7 g/day to 28 g/day. Commercial resveratrol supplements typically contain 500 mg/capsule, 
with a daily dosage of one capsule. This supplement may not provide a high enough dosage of 
resveratrol to induce the physiological adaptations seen in animal studies. Of the commercially 
available resveratrol supplements, one particular liquid supplement provided only 100 mg/day 
with the recommended dose. The amount of resveratrol present in this supplement may not be 
enough to induce the same physiological adaptations seen in animal or human studies. 
Efficacy of Resveratrol as an Exercise Mimetic 
 Resveratrol has been shown to function as an exercise mimetic. Physiological adaptations 
seen in response to endurance exercise include weight-loss, improved glucose tolerance and 
insulin sensitivity, increased mitochondrial biogenesis, and increases in VO2max and resistance 
to fatigue. Several animal studies have shown that resveratrol induces all of these adaptations as 
well as others (34, 45, 54). Currently, human studies have shown improvements in glucose 
tolerance and insulin sensitivity as well as several other factors, but an increase in mitochondrial 
biogenesis or aerobic capacity have not been observed (53). However, the adaptations that were 
observed in human studies are still consistent with adaptations seen in response to endurance 
exercise. Therefore, resveratrol does function as an exercise mimetic, but as of yet, human 
studies have not been able to attain all of the resveratrol-induced adaptations observed in animals 
studies. Nonetheless, commercially available resveratrol supplements may not induce any 
adaptations due to the low levels of resveratrol within the supplement. 
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Conclusion.  
The mechanism through which resveratrol functions as an exercise mimetic is complex. 
The pathway is not linear, but rather continual. Based on the studies examined in this paper, 
several conclusions can be made.  
PGC-1α activation is the determining factor regulating expression of NEMP and 
mitochondrial biogenesis. This is supported by the lack of mitochondrial biogenesis in PGC-1α 
knockout mice and the enhanced mitochondrial biogenesis in PGC-1α overexpression mice (7, 
35). Furthermore, increases in transcription of NEMP and mitochondrial biogenesis results in a 
shift towards a more oxidative muscle fiber phenotype (23).  
Resveratrol directly activates SIRT1 resulting in subsequent activation of PGC-1α. 
Resveratrol supplementation has been shown to increase SIRT1 activity by allosteric interactions 
with SIRT1, establishing an increased affinity of SIRT1for NAD+ and acetylated substrates (26). 
This allows for an increase in the deacetylation and partial activation of PGC-1α.  
Resveratrol directly activates AMPK causing an increase in PGC-1α activity. Resveratrol 
is shown to increase phosphorylation of AMPK, although the exact mechanism is unclear (4). 
AMPK phosphorylates PGC-1α, increasing its protein stability and partially activating it (30).  
SIRT1 and AMPK activation are reciprocally induced. AMPK induces SIRT1 activation 
by increasing available NAD+ for use in deacetylation reactions, leading to increased 
deacetylation of PGC-1α (9, 58). This supports the theory that resveratrol indirectly regulates 
SIRT1 activity. Meanwhile, SIRT1 is also shown to activate AMPK by deacetylating LKB1 
(liver kinase B1), the primary kinase responsible for phosphorylating and activating AMPK (28).  
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This suggests the possibility that SIRT1 is the major target of resveratrol. The proposed 
mechanism of resveratrol-mediated mitochondrial biogenesis can be seen in figure 7. 
The majority of the literature reviewed in this paper supports the theory that resveratrol 
directly activates both SIRT1 and AMPK. SIRT1 overexpression and SIRT1-knockout data 
strongly imply that SIRT1 is essential for mitochondrial biogenesis as well as resveratrol-
mediated AMPK activation (45). Although, a high dosage of resveratrol has been shown to 
activate AMPK in a SIRT1-independent manner, mitochondrial adaptations do not occur (45). 
This supports the hypothesis that SIRT1 is necessary for resveratrol-induced mitochondrial 
biogenesis. AMPK-knockout mice provide strong evidence that AMPK is imperative for 
resveratrol-induced mitochondrial adaptations, since mitochondrial biogenesis did not occur in 
Figure 7. Mechanism of action for resveratrol functioning as an exercise mimetic. 
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AMPK-knockout mice (54). SIRT1-dependent deacetylation of PGC-1α was shown to be 
partially blocked in AMPK-knockout mice (10).  
These results support the idea that AMPK and SIRT1 each partially activate PGC-1α, and 
without one or the other, there is no significant increase, or full activation, in PGC-1α activity; 
therefore mitochondrial biogenesis is not induced. Activation of AMPK has been shown to 
precede and regulate alterations in SIRT1 activity (10). It has been implied that phosphorylation 
of PGC-1α by AMPK may serve as a signal for SIRT1-induced deacetylation of PGC-1α (30). In 
conclusion, the mechanism of action responsible for resveratrol’s ability to function as an 
exercise mimetic is dependent upon direct activation of both AMPK and SIRT1. 
Future research in resveratrol and exercise mimetics 
 Future research needs to be done to determine the principal dosage of resveratrol required 
to exploit its physiological adaptations. Determining the correct dosage can lead to developing a 
more potent exercise mimetic which could be used to treat several diseases, including metabolic 
disorders and cardiovascular disease. 
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